{"id":988592,"date":"2026-08-03T10:49:02","date_gmt":"2026-08-03T14:49:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/"},"modified":"2026-08-03T10:49:02","modified_gmt":"2026-08-03T14:49:02","slug":"exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/","title":{"rendered":"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WILMINGTON, Del., Aug.  03, 2026  (GLOBE NEWSWIRE) &#8212; Exicure, Inc. (Nasdaq: XCUR) (\u201cExicure\u201d or the \u201cCompany\u201d) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (\u201cGPCR Therapeutics\u201d) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties\u2019 License and Collaboration Agreement.<\/p>\n<p align=\"justify\">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.<\/p>\n<p align=\"justify\">The shares are expected to be issued at a deemed value of $5.81 per share, based on applicable Nasdaq trading data, representing an aggregate deemed value of approximately $1.0 million.<\/p>\n<p align=\"justify\">On July 31, 2026, the Company submitted a Listing of Additional Shares Notification to The Nasdaq Stock Market in connection with the equity issuance. The Company also completed and delivered the applicable treasury issuance instructions to its transfer agent, Equiniti Trust Company, LLC.<\/p>\n<p align=\"justify\">The Company expects the issuance to be completed during August 2026, subject to the completion of customary Nasdaq and transfer agent review and processing procedures. Exicure intends to provide an additional update following completion of the issuance.<\/p>\n<p align=\"justify\">\u201cSettling this milestone payment through the issuance of common stock will allow Exicure to preserve cash and maintain financial flexibility as we continue to pursue our operational and strategic priorities,\u201d said Jung Soo Kim, Chief Executive Officer of Exicure.<\/p>\n<p align=\"justify\">\n        <strong>About Exicure, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company\u2019s lead program is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the anticipated issuance of shares to GPCR Therapeutics, the expected timing and completion of the issuance, the settlement of the Company\u2019s milestone payment obligation, and the Company\u2019s strategic direction. Forward-looking statements are based on management\u2019s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.<\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Exicure, Inc.<br \/>pr@exicuretx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2FkMzU1ZDUtODZhNi00MjUzLTg2YWItNWQ0OTdiMDE5ZDY4LTEwMzE4MDctMjAyNi0wOC0wMy1lbg==\/tiny\/Exicure-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) &#8212; Exicure, Inc. (Nasdaq: XCUR) (\u201cExicure\u201d or the \u201cCompany\u201d) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (\u201cGPCR Therapeutics\u201d) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties\u2019 License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026. The shares are expected to be issued at a deemed value of $5.81 per share, based on applicable Nasdaq trading data, representing an aggregate deemed value of approximately &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-988592","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) &#8212; Exicure, Inc. (Nasdaq: XCUR) (\u201cExicure\u201d or the \u201cCompany\u201d) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (\u201cGPCR Therapeutics\u201d) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties\u2019 License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026. The shares are expected to be issued at a deemed value of $5.81 per share, based on applicable Nasdaq trading data, representing an aggregate deemed value of approximately &hellip; Continue reading &quot;Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T14:49:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance\",\"datePublished\":\"2026-08-03T14:49:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/\"},\"wordCount\":436,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/\",\"name\":\"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=\",\"datePublished\":\"2026-08-03T14:49:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/","og_locale":"en_US","og_type":"article","og_title":"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Market Newsdesk","og_description":"WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) &#8212; Exicure, Inc. (Nasdaq: XCUR) (\u201cExicure\u201d or the \u201cCompany\u201d) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (\u201cGPCR Therapeutics\u201d) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties\u2019 License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026. The shares are expected to be issued at a deemed value of $5.81 per share, based on applicable Nasdaq trading data, representing an aggregate deemed value of approximately &hellip; Continue reading \"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-03T14:49:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance","datePublished":"2026-08-03T14:49:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/"},"wordCount":436,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/","name":"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=","datePublished":"2026-08-03T14:49:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjQ2NCM3NzU1NTY1IzIwMjAyMzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=988592"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988592\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=988592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=988592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=988592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}